Thrombolytic therapy as early management of ischemic stroke.
Killeen
I
I
D000208:Acute Disease; D001241:Aspirin / Q000009:adverse effects; D002545:Brain Ischemia / Q000150:complications*; D002543:Cerebral Hemorrhage / Q000139:chemically induced*; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000209:etiology; D005343:Fibrinolytic Agents / Q000009:adverse effects; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D013300:Streptokinase / Q000009:adverse effects; D015912:Thrombolytic Therapy / Q000009:adverse effects* / Q000592:standards; D013997:Time Factors
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D013300:Streptokinase; D001241:Aspirin